BackRecursion Pharmaceuticals Overview
Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Target Price

Analysts' average 12-month price target for Recursion Pharmaceuticals is $5.5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.31

Average Target Price

$5.5066.2% upside

1 analysts in the last 4 months

High: $5.5 | Low: $5.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-14Morgan Stanley$5.566.2% upsideOpen
2025-12-17UBS$11232.3% upsideOpen
2025-12-17Morgan Stanley$11232.3% upsideOpen
2025-02-28Leerink Partners$681.3% upsideOpen
2024-09-04NeedhamGil Blum$11232.3% upsideOpen
2024-09-03KeyBancScott Schoenhaus$12262.5% upsideOpen
2024-09-03JefferiesDennis Ding$681.3% upsideOpen
2024-06-26KeyBancScott Schoenhaus$16383.4% upsideOpen

Recursion Pharmaceuticals (RXRX) FAQ

As of the most recent data, RXRX shows a target price of $5.5. Scroll down for historical charts and peer comparison views.

If Recursion Pharmaceuticals moved to the average analyst target of $5.5, shares would be roughly 66.2% higher than $3.31. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Recursion Pharmaceuticals's earnings trajectory.

Besides this target price page, Stockcircle has Recursion Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $5.5) with ownership activity and broader fundamentals.

Recursion Pharmaceuticals's target price is $5.5; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.